Monte Rosa Therapeutics (GLUE) Total Liabilities (2023 - 2025)
Historic Total Liabilities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $214.0 million.
- Monte Rosa Therapeutics' Total Liabilities rose 9521.82% to $214.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.0 million, marking a year-over-year increase of 9521.82%. This contributed to the annual value of $215.8 million for FY2024, which is 7332.32% up from last year.
- As of Q3 2025, Monte Rosa Therapeutics' Total Liabilities stood at $214.0 million, which was up 9521.82% from $91.5 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Total Liabilities registered a high of $215.8 million during Q4 2024, and its lowest value of $65.0 million during Q2 2023.
- For the 3-year period, Monte Rosa Therapeutics' Total Liabilities averaged around $118.6 million, with its median value being $114.2 million (2024).
- Data for Monte Rosa Therapeutics' Total Liabilities shows a peak YoY increase of 9521.82% (in 2025) and a maximum YoY decrease of 2338.94% (in 2025) over the last 5 years.
- Over the past 3 years, Monte Rosa Therapeutics' Total Liabilities (Quarter) stood at $124.5 million in 2023, then skyrocketed by 73.32% to $215.8 million in 2024, then dropped by 0.83% to $214.0 million in 2025.
- Its Total Liabilities stands at $214.0 million for Q3 2025, versus $91.5 million for Q2 2025 and $118.0 million for Q1 2025.